Scalable Downstream Strategies for Purification of Recombinant Adeno-Associated Virus Vectors in Light of the Properties

被引:50
|
作者
Qu, Weihong [1 ,2 ,3 ,4 ]
Wang, Mingxi [1 ,2 ,3 ]
Wu, Yaqing [1 ,2 ,3 ]
Xu, Ruian [1 ,2 ,3 ]
机构
[1] Huaqiao Univ, Sch Med, Yunleung Lab Mol Diagnost, Quanzhou 362021, Peoples R China
[2] Huaqiao Univ, Inst Mol Med, Quanzhou 362021, Peoples R China
[3] Minist Educ, Engn Res Ctr Mol Med, Xiamen 361021, Peoples R China
[4] Jiujiang Univ, Coll Med & Life Sci, Jiujiang 332000, Jiangxi, Peoples R China
基金
中国国家自然科学基金;
关键词
Clinical application; downstream purification; large scale; physicochemical properties; purification strategy; rAAV vector; ION-EXCHANGE CHROMATOGRAPHY; LIPOPROTEIN-LIPASE DEFICIENCY; SERUM-FREE PRODUCTION; HUMAN GENE-THERAPY; VIRAL VECTORS; HIGH-TITER; COLUMN CHROMATOGRAPHY; EMPTY CAPSIDS; LARGE-SCALE; IN-VIVO;
D O I
10.2174/1389201016666150505122228
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Recombinant adeno-associated virus (rAAV) vector is one of the promising delivery tools for gene therapy. Currently, hundreds of clinical trials are performed but the major barrier for clinical application is the absence of any ideal large scale production technique to obtain sufficient and highly pure rAAV vector. The large scale production technique includes upstream and downstream processing. The upstream processing is a vector package step and the downstream processing is a vector purification step. For large scale downstream processing, the scientists need to recover rAAV from dozens of liters of cell lysate or medium, and a variety of purification strategies have been developed but not comprehensively compared till now. Consequently, this review will evaluate the scalable downstream purification strategies systematically, especially those based on the physicochemical properties of AAV virus, and attempt to find better scalable downstream strategies for rAAV vectors.
引用
收藏
页码:684 / 695
页数:12
相关论文
共 50 条
  • [41] Adenovirus and adeno-associated virus vectors
    Lai, CM
    Lai, YKY
    Rakoczy, PE
    DNA AND CELL BIOLOGY, 2002, 21 (12) : 895 - 913
  • [42] Adeno-associated virus vectors and hematology
    Russell, DW
    Kay, MA
    BLOOD, 1999, 94 (03) : 864 - +
  • [43] Chromatooraphic purification of recombinant adenoviral and adeno-associated viral vectors: methods and implications
    Burova, E
    Loffe, E
    GENE THERAPY, 2005, 12 (Suppl 1) : S5 - S17
  • [44] Chromatographic purification of recombinant adenoviral and adeno-associated viral vectors: methods and implications
    E Burova
    E Ioffe
    Gene Therapy, 2005, 12 : S5 - S17
  • [45] Production, Purification and Characterization of Adeno-Associated Vectors
    Ayuso, Eduard
    Mingozzi, Federico
    Bosch, Fatima
    CURRENT GENE THERAPY, 2010, 10 (06) : 423 - 436
  • [46] Novel chromatographic process for the purification of recombinant Adeno-Associated Virus pseudotypes
    Moxley, M
    Fisher, D
    Green, AP
    Kierstead, TD
    MOLECULAR THERAPY, 2004, 9 : S163 - S163
  • [47] Scaleable chromatographic purification process for recombinant adeno-associated virus (rAAV)
    O'Riordan, CR
    Lachapelle, AL
    Vincent, KA
    Wadsworth, SC
    JOURNAL OF GENE MEDICINE, 2000, 2 (06): : 444 - 454
  • [48] A helper virus-free packaging system for recombinant adeno-associated virus vectors
    Collaco, RF
    Cao, XH
    Trempe, JP
    GENE, 1999, 238 (02) : 397 - 405
  • [49] Production of recombinant adeno-associated virus
    Gao, GP
    Wilson, JM
    Wivel, NA
    ADVANCES IN VIRUS RESEARCH, VOL 55, 2000, 55 : 529 - 543
  • [50] Oversized Recombinant Adeno-Associated Virus (rAAV) Vectors Are Associated with Decreased Capsid Stability
    Zhang, Junping
    Guo, Ping
    Chew, Helen
    Firrman, Jenni
    Liu, Linshu
    Liu, Dan
    Yu, Xiangping
    Sang, Nianli
    Diao, Yong
    Xiao, Weidong
    MOLECULAR THERAPY, 2018, 26 (05) : 49 - 50